Next Article in Journal
Parallel Reaction Monitoring: A Targeted Experiment Performed Using High Resolution and High Mass Accuracy Mass Spectrometry
Next Article in Special Issue
Cissus sicyoides: Pharmacological Mechanisms Involved in the Anti-Inflammatory and Antidiarrheal Activities
Previous Article in Journal
Repositioning of Thiourea-Containing Drugs as Tyrosinase Inhibitors
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(12), 28549-28565; doi:10.3390/ijms161226122

Plants as Factories for Human Pharmaceuticals: Applications and Challenges

1
Emergency Department, The Affiliated Hospital of Qingdao University, Qingdao 266003, China
2
Department of Natural Sciences Northeastern State University at Broken Arrow, Broken Arrow, OK 74014, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Chang Won Choi
Received: 19 September 2015 / Revised: 18 November 2015 / Accepted: 23 November 2015 / Published: 2 December 2015
(This article belongs to the Special Issue Plant-Derived Pharmaceuticals by Molecular Farming 2016)
View Full-Text   |   Download PDF [932 KB, uploaded 2 December 2015]   |  

Abstract

Plant molecular farming (PMF), defined as the practice of using plants to produce human therapeutic proteins, has received worldwide interest. PMF has grown and advanced considerably over the past two decades. A number of therapeutic proteins have been produced in plants, some of which have been through pre-clinical or clinical trials and are close to commercialization. Plants have the potential to mass-produce pharmaceutical products with less cost than traditional methods. Tobacco-derived antibodies have been tested and used to combat the Ebola outbreak in Africa. Genetically engineered immunoadhesin (DPP4-Fc) produced in green plants has been shown to be able to bind to MERS-CoV (Middle East Respiratory Syndrome), preventing the virus from infecting lung cells. Biosafety concerns (such as pollen contamination and immunogenicity of plant-specific glycans) and costly downstream extraction and purification requirements, however, have hampered PMF production from moving from the laboratory to industrial application. In this review, the challenges and opportunities of PMF are discussed. Topics addressed include; transformation and expression systems, plant bioreactors, safety concerns, and various opportunities to produce topical applications and health supplements. View Full-Text
Keywords: plant molecular farming; edible vaccine; humanized glycan; transient expression; seed platform plant molecular farming; edible vaccine; humanized glycan; transient expression; seed platform
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Yao, J.; Weng, Y.; Dickey, A.; Wang, K.Y. Plants as Factories for Human Pharmaceuticals: Applications and Challenges. Int. J. Mol. Sci. 2015, 16, 28549-28565.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top